Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells.
Ontology highlight
ABSTRACT: Cancer is one of the most common causes of death among adults. Chemotherapy is crucial in determining patient survival and quality of life. However, the development of multidrug resistance (MDR) continues to pose a significant challenge in the management of cancer. In this study, we analyzed the role of human ribosomal protein uL3 (formerly rpL3) in multidrug resistance. Our studies revealed that uL3 is a key determinant of multidrug resistance in p53-mutated lung cancer cells by controlling the cell redox status. We established and characterized a multidrug resistant Calu-6 cell line. We found that uL3 down-regulation correlates positively with multidrug resistance. Restoration of the uL3 protein level re-sensitized the resistant cells to the drug by regulating the reactive oxygen species
SUBMITTER: Russo A
PROVIDER: S-EPMC5372563 | biostudies-literature | 2017 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA